Loading...
•
Dec 31, 2023
ORIC Pharmaceuticals Q4 2023 Earnings Report
ORIC Pharmaceuticals reported financial results and operational updates for Q4 2023.
Key Takeaways
ORIC Pharmaceuticals reported a net loss of $28.33 million for the fourth quarter of 2023. The company's cash, cash equivalents, and investments totaled $235.0 million as of December 31, 2023, which is expected to fund the operating plan into late 2026.
Presented initial Phase 1b data from three clinical programs, supporting potential best-in-class profiles for ORIC-944 and ORIC-114.
Expect to initiate a combination study of ORIC-944 with AR inhibitor(s) in metastatic prostate cancer in the first half of 2024.
Expect to initiate multiple dose expansion cohorts for ORIC-114 in patients with mutated NSCLC in the first half of 2024.
Strengthened cash position with $210 million from two private placement financings.
ORIC Pharmaceuticals
ORIC Pharmaceuticals
Forward Guidance
ORIC Pharmaceuticals plans to advance two programs towards the initiation of registrational studies in the second half of 2025.
Positive Outlook
- Initiate combination study of ORIC-944 with AR inhibitor(s) in metastatic prostate cancer expected in first half of 2024.
- Provide a program update for ORIC-944 in mid-2024.
- Initiate multiple dose expansion cohorts for ORIC-114 in patients with mutated NSCLC expected in first half of 2024.
- Report updated Phase 1b data for ORIC-114 in the first half of 2025.
- Complete dose escalation for the Phase 1b trial of ORIC-533 in the first quarter of 2024.